News
Scientists discover the immunomodulatory activity of a drug that would improve the efficacy of immunotherapy against breast cancer
The team of Dr. Eva González-Suarez, from the CNIO and IDIBELL, and the team of Dr. Christos Sotiriou, from the Jules Bordet Institute, demonstrate that a drug already used to treat osteoporosis promotes the infiltration of immune cells in breast tumors.
The team led by Dr. M. Carolina Florian at IDIBELL receives a European grant of 2 million euros to study bone marrow rejuvenation
With this project, Dr. M Carolina Florian, from the IDIBELL’s Regenerative Medicine Program, aims to improve the survival and quality of life of elderly patients undergoing chemotherapy.
IDIBELL has held a meeting with the best Healthtech projects
The most innovative technology projects in the healthcare sector were presented this November 26th at the third edition of the Accelerator Meeting Point (AMP). The digital meeting allowed different IDIBELL entrepreneurs and invited entities from the HealthTech/Biotech sector to espouse their projects to investors and pharmaceutical companies to obtain financing.
La Marató will finance with 1.5 million euros 10 IDIBELL projects in rare diseases
IDIBELL has been one of the institutions with more funded projects, up to 10, of which it leads 7, and participates in 3 more projects as a collaborator.
New biomedical breakthroughs of Bellvitge, live streaming on November 28th
Next Saturday, November 28th, researchers of Bellvitge will present their most recent investigations to the general public. The new website Sinergia will broadcast a wide program of virtual talks. Sinergia has been specifically released to celebrate the first virtual edition of the Festival for the Research and Innovation in Health of L’Hospitalet.
The combination of two immunomodulatory drugs could be beneficial for more severe Covid-19 patients
A total of 44 researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital (HUB) sign an article in the International Journal of Infectious Diseases, where they demonstrate the beneficial effect of the use of corticosteroids added to tocilizumab treatment to improve the prognosis of critical patients of Covid-19.
Some drugs used to reduce stomach acid may increase false positives in the colon and rectal cancer screening
A new study analyzes the influence of proton pump inhibitor drugs on the risk of false positives in an immunological fecal occult blood test, a test used to detect colorectal cancer.
Bellvitge will study the application of artificial intelligence in the treatment of Covid-19 in ICUs
The Intensive Medicine Service of the Bellvitge University Hospital (HUB) participates, through the Bellvitge Biomedical Research Institute (IDIBELL), in the European ENVISION project, which will develop an intelligent decision support system to improve the monitoring and treatment of patients with Covid-19 in ICUs.
IDIBELL celebrates the Kickoff Meeting of the projects financed by 2019 La Marató de TV3 Foundation call
Today, the Teams platform hosted the IDIBELL Kickoff Meeting La Marató 2019, aimed at all those researchers who have obtained a research project within the “Convocatòria 2019 per a l’adjudicació d’ajudes econòmiques a projectes de recerca de càncer” by La La Marató de TV3 Foundation.